Affimed Announces Appointment of Andrew Curtis to Lead Corporate Strategy and Business Development, Expansion of US Presence

Press Release - December 2, 2015

Download Press Release

Heidelberg,  Germany,  December  2,  2015  –  Affimed  N.V.  (Nasdaq:  AFMD),  a  clinical-­stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that Andrew Curtis has joined Affimed as Head of Corporate Strategy and Business Development. He brings more than two decades of expertise from large pharmaceutical companies, most notably Pfizer, and as a biotechnology entrepreneur.

“As  a  seasoned  executive  in  both  the  pharmaceutical  and  biotechnology  industries,  Andrew has a remarkable insight and understanding of the strategic and marketing aspects  of  drug  development  and  commercialization,”  said  Dr.  Adi  Hoess,  CEO  of  Affimed. “We are excited to work with him in furthering Affimed’s goal of becoming a global  commercial  oncology  company  with  a  focus  on  NK-­cell  and  T-­cell  based  therapies.” Andrew  has  spent  more  than  twenty  years  in  the  pharmaceutical  and  biotechnology  sectors, focusing on the licensing, commercial development and commercialization of new medicines for rare and neglected diseases. Since leaving Pfizer in 2014, Andrew has been involved in entrepreneurial and advisory activities. At Pfizer, Andrew led the Specialty Care Business Unit’s External Opportunities and New Business team as well as Pfizer’s BioTherapeutic’s Business Innovation and Strategy team, focusing on novel Open Innovation models in support of the BioTherapeutics R&D organization. Previously, Andrew  was  Global  Team  Lead  for  the  Biosimilars  and  Orphan  Drugs  division  within  Pfizer’s Established Products Business Unit, where he crafted the company’s first-­ever rare disease unit and biosimilar program strategies.

Prior to rejoining Pfizer in 2008, Andrew was CEO of Jerini US Inc., a company focused on  the  development  and  commercialization  of  icatibant,  a  treatment  for  hereditary  angioedema, subsequently commercialized under the brand name Firazyr by Shire after it  acquired  Jerini  in  2008.  His  career  also  includes  commercial  marketing  and  sales  positions with Pfizer, Genzyme, TargetRx, J&J, and Merck. Andrew holds a B.A. from Muhlenberg College and a M.A. from Lehigh University.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed’s product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body’s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed’s proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit

Affimed IR Contact

Caroline Stewart, Head IR & Communication Phone: +1 347 394 6793
E-Mail: email hidden; JavaScript is required or email hidden; JavaScript is required

Media Requests

Stephanie May or Gretchen Schweitzer
MacDougall Biomedical Communications
Phone: +49 89 2424 3494 or +49 172 861 8540
E-Mail: email hidden; JavaScript is required